NCT04920916View on ClinicalTrials.gov

Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 25, 2021

Primary Completion Date

April 18, 2023

Study Completion Date

April 18, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

Dupilumab

Participants will receive a loading dose of dupilumab (600 mg, given as two 300 mg subcutaneous injections) on day 0/1. If participants are still hospitalized a second and third dose (300 mg) will be given on days 14 and 28.

DRUG

Placebo

Normal Saline.

Trial Locations (1)

22908

UVA Health, Charlottesville

All Listed Sponsors
collaborator

The Paul Manning Foundation

OTHER

collaborator

Virginia Catalyst

OTHER

lead

University of Virginia

OTHER